Association of NAT and GST polymorphisms with non-Hodgkin's lymphoma: A population-based case-control study

Brian C.H. Chiu, Carol Kolar, Susan M. Gapstur, Terence Lawson, James R. Anderson, Dennis D. Weisenburger

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Several chemicals have been associated with risk of non-Hodgkin's lymphoma (NHL), many of which are substrates for N-acetyltransferase (NAT) and glutathione S-transferase (GST) enzymes. We investigated the association between polymorphisms in genes coding for these enzymes and NHL risk in a population-based study (389 cases and 535 controls). NAT1 slow genotype was associated with a slightly increased risk in women [odds ratios (OR) = 1.4; 95% confidence interval (CI) = 0.9-2.3], but not in men. NAT2 slow genotype was not associated with risk in either sex. The two slow genotypes of NAT1 and NAT2 combined were associated with a minor increase of risk in women (OR = 1.4; 0.8-2.4). There was no association with the GSTM1 or GSTT1 null genotype in either sex, irrespective of histological subtypes. Individuals with GSTP1 Val homozygotes had non-significant excessive risk of marginal zone lymphoma (OR = 1.8; 0.6-5.1) and 'other' B-cell NHLs (OR = 1.6; 0.7-3.6), but lower risk of diffuse large B-cell lymphoma (OR = 0.2; 0.1-0.96). Risk did not elevate with an increasing number of high-risk GST alleles in either sex. In summary, although NAT1, NAT2, GSTM1, GSTT1, or GSTP1 polymorphisms do not appear to be associated with NHL risk overall, there might be gender-specific and subtype-specific associations that require confirmation.

Original languageEnglish (US)
Pages (from-to)610-615
Number of pages6
JournalBritish Journal of Haematology
Volume128
Issue number5
DOIs
StatePublished - Mar 1 2005

Fingerprint

Acetyltransferases
Glutathione Transferase
Non-Hodgkin's Lymphoma
Case-Control Studies
Population
Odds Ratio
Genotype
Lymphoma, Large B-Cell, Diffuse
Homozygote
Enzymes
Lymphoma
B-Lymphocytes
Alleles
Confidence Intervals

Keywords

  • Glutathione S-transferase
  • N-acetyltransferase
  • Non-Hodgkin's lymphoma
  • Polymorphism

ASJC Scopus subject areas

  • Hematology

Cite this

Association of NAT and GST polymorphisms with non-Hodgkin's lymphoma : A population-based case-control study. / Chiu, Brian C.H.; Kolar, Carol; Gapstur, Susan M.; Lawson, Terence; Anderson, James R.; Weisenburger, Dennis D.

In: British Journal of Haematology, Vol. 128, No. 5, 01.03.2005, p. 610-615.

Research output: Contribution to journalArticle

Chiu, Brian C.H. ; Kolar, Carol ; Gapstur, Susan M. ; Lawson, Terence ; Anderson, James R. ; Weisenburger, Dennis D. / Association of NAT and GST polymorphisms with non-Hodgkin's lymphoma : A population-based case-control study. In: British Journal of Haematology. 2005 ; Vol. 128, No. 5. pp. 610-615.
@article{632516fd216644d99c87c15685f0f19a,
title = "Association of NAT and GST polymorphisms with non-Hodgkin's lymphoma: A population-based case-control study",
abstract = "Several chemicals have been associated with risk of non-Hodgkin's lymphoma (NHL), many of which are substrates for N-acetyltransferase (NAT) and glutathione S-transferase (GST) enzymes. We investigated the association between polymorphisms in genes coding for these enzymes and NHL risk in a population-based study (389 cases and 535 controls). NAT1 slow genotype was associated with a slightly increased risk in women [odds ratios (OR) = 1.4; 95{\%} confidence interval (CI) = 0.9-2.3], but not in men. NAT2 slow genotype was not associated with risk in either sex. The two slow genotypes of NAT1 and NAT2 combined were associated with a minor increase of risk in women (OR = 1.4; 0.8-2.4). There was no association with the GSTM1 or GSTT1 null genotype in either sex, irrespective of histological subtypes. Individuals with GSTP1 Val homozygotes had non-significant excessive risk of marginal zone lymphoma (OR = 1.8; 0.6-5.1) and 'other' B-cell NHLs (OR = 1.6; 0.7-3.6), but lower risk of diffuse large B-cell lymphoma (OR = 0.2; 0.1-0.96). Risk did not elevate with an increasing number of high-risk GST alleles in either sex. In summary, although NAT1, NAT2, GSTM1, GSTT1, or GSTP1 polymorphisms do not appear to be associated with NHL risk overall, there might be gender-specific and subtype-specific associations that require confirmation.",
keywords = "Glutathione S-transferase, N-acetyltransferase, Non-Hodgkin's lymphoma, Polymorphism",
author = "Chiu, {Brian C.H.} and Carol Kolar and Gapstur, {Susan M.} and Terence Lawson and Anderson, {James R.} and Weisenburger, {Dennis D.}",
year = "2005",
month = "3",
day = "1",
doi = "10.1111/j.1365-2141.2004.05358.x",
language = "English (US)",
volume = "128",
pages = "610--615",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Association of NAT and GST polymorphisms with non-Hodgkin's lymphoma

T2 - A population-based case-control study

AU - Chiu, Brian C.H.

AU - Kolar, Carol

AU - Gapstur, Susan M.

AU - Lawson, Terence

AU - Anderson, James R.

AU - Weisenburger, Dennis D.

PY - 2005/3/1

Y1 - 2005/3/1

N2 - Several chemicals have been associated with risk of non-Hodgkin's lymphoma (NHL), many of which are substrates for N-acetyltransferase (NAT) and glutathione S-transferase (GST) enzymes. We investigated the association between polymorphisms in genes coding for these enzymes and NHL risk in a population-based study (389 cases and 535 controls). NAT1 slow genotype was associated with a slightly increased risk in women [odds ratios (OR) = 1.4; 95% confidence interval (CI) = 0.9-2.3], but not in men. NAT2 slow genotype was not associated with risk in either sex. The two slow genotypes of NAT1 and NAT2 combined were associated with a minor increase of risk in women (OR = 1.4; 0.8-2.4). There was no association with the GSTM1 or GSTT1 null genotype in either sex, irrespective of histological subtypes. Individuals with GSTP1 Val homozygotes had non-significant excessive risk of marginal zone lymphoma (OR = 1.8; 0.6-5.1) and 'other' B-cell NHLs (OR = 1.6; 0.7-3.6), but lower risk of diffuse large B-cell lymphoma (OR = 0.2; 0.1-0.96). Risk did not elevate with an increasing number of high-risk GST alleles in either sex. In summary, although NAT1, NAT2, GSTM1, GSTT1, or GSTP1 polymorphisms do not appear to be associated with NHL risk overall, there might be gender-specific and subtype-specific associations that require confirmation.

AB - Several chemicals have been associated with risk of non-Hodgkin's lymphoma (NHL), many of which are substrates for N-acetyltransferase (NAT) and glutathione S-transferase (GST) enzymes. We investigated the association between polymorphisms in genes coding for these enzymes and NHL risk in a population-based study (389 cases and 535 controls). NAT1 slow genotype was associated with a slightly increased risk in women [odds ratios (OR) = 1.4; 95% confidence interval (CI) = 0.9-2.3], but not in men. NAT2 slow genotype was not associated with risk in either sex. The two slow genotypes of NAT1 and NAT2 combined were associated with a minor increase of risk in women (OR = 1.4; 0.8-2.4). There was no association with the GSTM1 or GSTT1 null genotype in either sex, irrespective of histological subtypes. Individuals with GSTP1 Val homozygotes had non-significant excessive risk of marginal zone lymphoma (OR = 1.8; 0.6-5.1) and 'other' B-cell NHLs (OR = 1.6; 0.7-3.6), but lower risk of diffuse large B-cell lymphoma (OR = 0.2; 0.1-0.96). Risk did not elevate with an increasing number of high-risk GST alleles in either sex. In summary, although NAT1, NAT2, GSTM1, GSTT1, or GSTP1 polymorphisms do not appear to be associated with NHL risk overall, there might be gender-specific and subtype-specific associations that require confirmation.

KW - Glutathione S-transferase

KW - N-acetyltransferase

KW - Non-Hodgkin's lymphoma

KW - Polymorphism

UR - http://www.scopus.com/inward/record.url?scp=14844307841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14844307841&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2004.05358.x

DO - 10.1111/j.1365-2141.2004.05358.x

M3 - Article

C2 - 15725081

AN - SCOPUS:14844307841

VL - 128

SP - 610

EP - 615

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -